Top

Published in:

01-02-2010 | Epidemiology

Tumor marker phenotype concordance in second primary breast cancer, California, 1999–2004

Authors: Monica Brown, Katrina Bauer, Mary Pare

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Abstract

Breast cancer is the most common cancer among women. It is estimated that 7% of women who have breast cancer will develop a subsequent second independent breast tumor within 10 years of the first. The status of estrogen (ER), progesterone (PR) and human growth hormone (HER2) receptors, individually and as phenotypic combinations, impacts the clinical course of breast cancer and may impact the course of subsequent primary tumors and patient survival. Our aims were to determine tumor marker phenotype concordance between first and second primary breast cancers (FPBC and SPBC), describe demographic and clinical characteristics, and examine first tumor treatments associated with phenotype concordance. A total of 76,209 cases of female invasive breast cancer were identified in the California Cancer Registry from 1999 to 2004. Of those, 1,407 women who had not undergone a prophylactic mastectomy, had information on the status of three tumor markers, and were diagnosed with an SPBC during the study period were selected. SPBCs were significantly smaller, diagnosed at a higher stage and were node positive. Patients whose FPBC was ER⁺/−/PR⁺/−/HER2− and triple negative (TN) (ER−/PR−/HER2−), often had concordant phenotypes for their SPBC. ER⁺/−/PR⁺/−/HER2+ and HER2-positive (ER−/PR−/HER2+) FPBCs, often had discordant phenotypes for their SPBC. ER⁺/−/PR⁺/−/HER2− SPBCs often lacked HER2 expression and were ER and/or PR positive. Tumor laterality and synchronicity significantly predicted concordance as did having a FPBC whose phenotypes were ER⁺/−/PR⁺/−/HER2+, HER2-positive and TN, while first primary tumor treatment with chemotherapy predicted discordance. The relationship between multiple primary breast cancer phenotype concordance and patient prognosis has yet to be determined. Our results indicate that SPBC surveillance strategies include consideration of FPBC phenotype. Although our results are provocative, they may have been influenced by current criteria used to determine tumor independence.

American Cancer Society (2008) California Facts, Figs 2008. California Division and Public Health Institute, California Cancer Registry, Oakland, CA

Healey EA, Cook EF, Orav EJ, Schnitt SJ, Connolly JL, Harris JR (1993) Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol 11:1545–1552PubMed

Verkooijen HM, Chatelain V, Fioretta G, Vlastos G, Rapiti E, Sappino AP, Bouchardy C, Chappuis PO (2007) Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat 105:347–357. doi:10.1007/s10549-006-9455-x CrossRefPubMed

Kollias J, Ellis IO, Elston CW, Blamey RW (2001) Prognostic significance of synchronous and metachronous bilateral breast cancer. World J Surg 25:1117–1124PubMed

Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO, Dickman PW, Hall P (2007) Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol 25:4210–4216. doi:10.1200/JCO.2006.10.5056 CrossRefPubMed

Michowitz M, Noy S, Lazebnik N, Aladjem D (1985) Bilateral breast cancer. J Surg Oncol 30:109–112. doi:10.1002/jso.2930300210 CrossRefPubMed

Heron DE, Komarnicky LT, Hyslop T, Schwartz GF, Mansfield CM (2000) Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer 88:2739–2750. doi:10.1002/1097-0142(20000615)88:12<2739::AID-CNCR12>3.0.CO;2-J CrossRefPubMed

Takahashi H, Watanabe K, Takahashi M, Taguchi K, Sasaki F, Todo S (2005) The impact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer. Breast Cancer 12:196–202. doi:10.2325/jbcs.12.196 CrossRefPubMed

Bernstein JL, Lapinski RH, Thakore SS, Doucette JT, Thompson WD (2003) The descriptive epidemiology of second primary breast cancer. Epidemiology 14:552–558. doi:10.1097/01.ede.0000072105.39021.6d CrossRefPubMed

10.

Gogas J, Markopoulos C, Skandalakis P, Gogas H (1993) Bilateral breast cancer. Am Surg 59:733–735PubMed

11.

Broet P, de la Rochefordiere A, Scholl SM, Fourquet A, Mosseri V, Durand JC, Pouillart P, Asselain B (1995) Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol 13:1578–1583PubMed

12.

Schaapveld M, Visser O, Louwman WJ, Willemse PHB, de Vries EGE, van der Graaf WTA, Otter R, Coebergh JWW, van Leeuwen FE (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189–197

13.

Engin K (1994) Prognostic factors in bilateral breast cancer. Neoplasma 41:353–357PubMed

14.

Kollias J, Ellis IO, Elston CW, Blamey RW (1999) Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol 25:584–589. doi:10.1053/ejso.1999.0711 CrossRefPubMed

15.

Bernstein JL, Thompson WD, Risch N, Holford TR (1992) The genetic epidemiology of second primary breast cancer. Am J Epidemiol 136:937–948PubMed

16.

Kuo WH, Yen AM, Lee PH, Hou MF, Chen SC, Chen KM, Chen TH, Chang KJ (2006) Incidence and risk factors associated with bilateral breast cancer in area with early age diagnosis but low incidence of primary breast cancer: analysis of 10-year longitudinal cohort in Taiwan. Breast Cancer Res Treat 99:221–228. doi:10.1007/s10549-006-9194-z CrossRefPubMed

17.

Newman LA, Sahin AA, Cunningham JE, Bondy ML, Mirza NQ, Vlastos GS, Whitman GJ, Brown H, Buchholz TA, Lee MH et al (2001) A case-control study of unilateral and bilateral breast carcinoma patients. Cancer 91:1845–1853. doi:10.1002/1097-0142(20010515)91:10<1845::AID-CNCR1205>3.0.CO;2-Z CrossRefPubMed

18.

Schwartz AG, Ragheb NE, Swanson GM, Satariano WA (1989) Racial and age differences in multiple primary cancers after breast cancer: a population-based analysis. Breast Cancer Res Treat 14:245–254. doi:10.1007/BF01810741 CrossRefPubMed

19.

Yeatman TJ, Lyman GH, Smith SK, Reintgen DS, Cantor AB, Cox CE (1997) Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment. Ann Surg Oncol 4:198–202. doi:10.1007/BF02306610 CrossRefPubMed

20.

Bernstein JL, Thompson WD, Risch N, Holford TR (1992) Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol 136:925–936PubMed

21.

Gao X, Fisher SG, Emami B (2003) Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys 56:1038–1045. doi:10.1016/S0360-3016(03)00203-7 CrossRefPubMed

22.

Berte E, Buzdar AU, Smith TL, Hortobagyi GN (1988) Bilateral primary breast cancer in patients treated with adjuvant therapy. Am J Clin Oncol 11:114–118PubMedCrossRef

23.

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752. doi:10.1038/35021093 CrossRefPubMed

24.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502. doi:10.1001/jama.295.21.2492 CrossRefPubMed

25.

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728. doi:10.1002/cncr.22618 CrossRefPubMed

26.

Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V (2008) The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999–2004. Cancer 112:737–747. doi:10.1002/cncr.23243 CrossRefPubMed

27.

Intra M, Rotmensz N, Viale G, Mariani L, Bonanni B, Mastropasqua MG, Galimberti V, Gennari R, Veronesi P, Colleoni M et al (2004) Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. Cancer 101:905–912. doi:10.1002/cncr.20452 CrossRefPubMed

28.

Matsuo K, Fukutomi T, Tsuda H, Akashi-Tanaka S, Shimizu C, Hasegawa T (2001) Differences in estrogen receptor status, HER2, and p53 comparing metachronous bilateral breast carcinoma. J Surg Oncol 77:31–34. doi:10.1002/jso.1062 CrossRefPubMed

29.

Geiger AM, Thwin SS, Lash TL, Buist DS, Prout MN, Wei F, Field TS, Ulcickas Yood M, Frost FJ, Enger SM et al (2007) Recurrences and second primary breast cancers in older women with initial early-stage disease. Cancer 109:966–974. doi:10.1002/cncr.22472 CrossRefPubMed

30.

Coradini D, Oriana S, Mariani L, Miceli R, Bresciani G, Marubini E, Di Fronzo G (1998) Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? Eur J Cancer 34:825–830. doi:10.1016/S0959-8049(97)10121-6 CrossRefPubMed

31.

Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:21–33. doi:10.1038/nrg1748 CrossRefPubMed

32.

Zangwill M (2006) Eight years after its approval, Herceptin emerges as the best weapon against HER2-positive breast cancer. Cure 5

33.

Fritz AG (2000) International classification of diseases for oncology: ICD-O, 3rd edn. World Health Organization, Geneva

34.

Cancer reporting in California: standards for automated reporting (2006) California cancer reporting system standards, volume II. In: Sacramento: California Department of Health Services, Cancer Surveillance Section

35.

Johnson CH, Adamo M (eds) (2007) The SEER program coding manual 2007. National Cancer Institute, Bethesda

36.

Cancer reporting in California abstracting and coding procedures for hospitals (2007). California cancer reporting system standards, volume I. In: Sacramento: California Department of Health Services, Cancer Surveillance and Research Branch

37.

Bauer KR, Brown M, Creech C, Schlag NC, Caggiano V (2007) Data quality assessment of HER2 in the Sacramento Region of the California Cancer Registry. J Regist Manag 34:4–7

38.

Stewart SL, Swallen KC, Glaser SL, Horn-Ross PL, West DW (1999) Comparison of methods for classifying Hispanic ethnicity in a population-based cancer registry. Am J Epidemiol 149:1063–1071PubMed

39.

Yost K, Perkins C, Cohen R, Morris C, Wright W (2001) Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12:703–711. doi:10.1023/A:1011240019516 CrossRefPubMed

40.

Rural Urban Commuting Area Code In: US Department of Agriculture Economic Research Service, 2001, Washington, DC, vol. 2004; 2006

41.

The use of RUCAS (version 2.0) in health care (http://depts.washington.edu/uwruca/uses.html)

42.

Greene FL, American Joint Committee on Cancer, American Cancer Society (2002) AJCC cancer staging manual, 6th edn. Springer-Verlag, New York

43.

SEER Extent of Disease (1998) Codes and coding instructions, 3rd edn. National Cancer Institute, National Institutes of Health, Bethesda

44.

Collaborative Staging Task Force of the American Joint Committee on Cancer (2004) Collaborative staging manual and coding instructions, version 01.03.00. Jointly published by American Joint Committee on Cancer and U.S. Department of Health and Human Services, Chicago and Bethesda

45.

Fleiss JL, Levin BA, Paik MC (2003) Statistical methods for rates and proportions, 3rd edn. Wiley, Hoboken

46.

Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174. doi:10.2307/2529310 CrossRefPubMed

47.

Collins LC, Schnitt SJ, Colditz GA, Deitz AC, Baer HJ, Chen WY, Connolly JL, Rubin M, Fu Y, Rosner B et al (2006) Risk factors for luminal, HER2, and basal-like breast cancer subtypes: results from a tissue microarray-based analysis of invasive breast cancers from women enrolled in the nurses’ health study. Breast Cancer Res Treat 100:S275 Abstract 5041

48.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334. doi:10.1158/1078-0432.CCR-06-1109 CrossRefPubMed

49.

Kang SP, Martel M, Harris LN (2008) Triple negative breast cancer: current understanding of biology and treatment options. Curr Opin Obstet Gynecol 20:40–46. doi:10.1097/GCO.0b013e3282f40de9 CrossRefPubMed

50.

Allan JM, Travis LB (2005) Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 5:943–955. doi:10.1038/nrc1749 CrossRefPubMed

51.

Amadori D, Ronconi S (2005) Secondary lung tumors in hematological patients. Semin Respir Crit Care Med 26:520–526. doi:10.1055/s-2005-922035 CrossRefPubMed

52.

Abramovitz M, Leyland-Jones B (2007) Application of array-based genomic and epigenomic technologies to unraveling the heterogeneous nature of breast tumors: on the road to individualized treatment. Cancer Genomics Proteomics 4:135–145PubMed

53.

Tonon G (2008) From oncogene to network addiction: the new frontier of cancer genomics and therapeutics. Future Oncol 4:569–577. doi:10.2217/14796694.4.4.569 CrossRefPubMed

54.

Weitzel JN, Robson M, Pasini B, Manoukian S, Stoppa-Lyonnet D, Lynch HT, McLennan J, Foulkes WD, Wagner T, Tung N et al (2005) A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev 14:1534–1538. doi:10.1158/1055-9965.EPI-05-0070 CrossRefPubMed

55.

Cooney CS, Khouri NF, Tsangaris TN (2008) The role of breast MRI in the management of patients with breast disease. Adv Surg 42:299–312. doi:10.1016/j.yasu.2008.03.003 CrossRefPubMed

56.

Partridge SC (2008) Future applications and innovations of clinical breast magnetic resonance imaging. Top Magn Reson Imaging 19:171–176. doi:10.1097/RMR.0b013e31818a4090 CrossRefPubMed

57.

Warner E (2008) The role of magnetic resonance imaging in screening women at high risk of breast cancer. Top Magn Reson Imaging 19:163–169. doi:10.1097/RMR.0b013e31818bc994 CrossRefPubMed

58.

MacFarlane R, Speers C, Masoudi H, Chia S (2008) Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population-based database and tissue microarray series. J Clin Oncol May 20 suppl, abstract 1000

59.

Broglio K, Moulder SL, Hsu L, Kau S, Pusztai L, Symmans WF, Hortobagyi GN, Gonzalez-Angulo AM, Liedtke C (2008) Prognostic impact of discordance/concordance of triple-receptor expression between primary tumor and metastasis in patients with metastatic breast cancer. J Clin Oncol May 20 suppl, abstract 1001

60.

Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R (2008) Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res 68:7493–7501. doi:10.1158/0008-5472.CAN-08-1404 CrossRefPubMed

61.

Dawood S, Resetkova E, Gonzalez-Angulo AM (2008) Trastuzumab administration associated with change in HER2 status. Clin Breast Cancer 8:366–369. doi:10.3816/CBC.2008.n.044 CrossRefPubMed

62.

Asgeirsson KS, Agrawal A, Allen C, Hitch A, Ellis IO, Chapman C, Cheung KL, Robertson JF (2007) Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Breast Cancer Res 9:R75. doi:10.1186/bcr1788 CrossRefPubMed

63.

Tapia C, Savic S, Wagner U, Schonegg R, Novotny H, Grilli B, Herzog M, Barascud AD, Zlobec I, Cathomas G et al (2007) HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 9:R31. doi:10.1186/bcr1676 CrossRefPubMed

64.

Varga Z, Caduff R, Pestalozzi B (2005) Stability of the HER2 gene after primary chemotherapy in advanced breast cancer. Virchows Arch 446:136–141. doi:10.1007/s00428-004-1164-4 CrossRefPubMed

65.

Felsher DW (2008) Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res 68:3081–3086. doi:10.1158/0008-5472.CAN-07-5832 discussion 3086CrossRefPubMed

66.

Thor A (2001) HER2—a discussion of testing approaches in the USA. Ann Oncol 12(Suppl 1):S101–S107. doi:10.1023/A:1011120309910 CrossRefPubMed

67.

Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ et al (2006) HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Cancer Netw 4(Suppl 3):S1–S22 quiz S23-S24

68.

Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Daling JR (2003) The relationship between alcohol use and risk of breast cancer by histology and hormone receptor status among women 65–79 years of age. Cancer Epidemiol Biomarkers Prev 12:1061–1066PubMed

69.

Fair AM, Montgomery K (2009) Energy balance, physical activity, and cancer risk. Methods Mol Biol 472:57–88. doi:10.1007/978-1-60327-492-0_3 CrossRefPubMed

70.

Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95:1467–1476PubMed

71.

Demark-Wahnefried W, Rimer BK, Winer EP (1997) Weight gain in women diagnosed with breast cancer. J Am Diet Assoc 97:519–526, 529. quiz 527–518. doi:10.1016/S0002-8223(97)00133-8

72.

Parise C, Caggiano V, Brown M, Bauer K (2008) Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999–2004. The Breast Journal in publication

73.

Li CI, Daling JR, Malone KE (2003) Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 21:28–34. doi:10.1200/JCO.2003.03.088 CrossRefPubMed

74.

Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI (2005) Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 103:2241–2251. doi:10.1002/cncr.21030 CrossRefPubMed

75.

Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9:R6. doi:10.1186/bcr1639 CrossRefPubMed

76.

Cress RD, Zaslavsky AM, West DW, Wolf RE, Felter MC, Ayanian JZ (2003) Completeness of information on adjuvant therapies for colorectal cancer in population-based cancer registries. Med Care 41:1006–1012. doi:10.1097/01.MLR.0000083740.12949.88 CrossRefPubMed

77.

Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA (2002) Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst 94:835–844PubMed

78.

Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL (2005) BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 91:179–186. doi:10.1007/s10549-004-7603-8 CrossRefPubMed

79.

Ribeiro-Silva A, Ramalho LN, Garcia SB, Brandao DF, Chahud F, Zucoloto S (2005) p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 47:458–466. doi:10.1111/j.1365-2559.2005.02249.x CrossRefPubMed

80.

De Maeyer L, Van Limbergen E, De Nys K, Moerman P, Pochet N, Hendrickx W, Wildiers H, Paridaens R, Smeets A, Christiaens MR et al (2008) Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? J Clin Oncol 26:335–336. doi:10.1200/JCO.2007.14.8411 author reply 336–338CrossRefPubMed

Title: Tumor marker phenotype concordance in second primary breast cancer, California, 1999–2004
Authors: Monica Brown
Katrina Bauer
Mary Pare
Publication date: 01-02-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0469-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Impact of obesity on diagnosis and treatment of breast cancer

Evaluation of malignancy-risk gene signature in breast cancer patients

CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification

Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature

Association of BTLA gene polymorphisms with the risk of malignant breast cancer in Chinese women of Heilongjiang Province

Mutation screening of breast cancer susceptibility genes in Chinese high-risk families: the results will develop the genetic testing strategy in China

Keynote webinar | Spotlight on antibody–drug conjugates in cancer